Raptor Pharmaceuticals Corp. to Present at 2009 Cystinosis Research Network Family ...(any products or acquiring products; that...),Health

Date:7/16/2009

any products or acquiring products; that Raptor's technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; that Raptor is unable to retain or attract key employees whose knowledge is essential to the development of its products; that unforeseen scientific difficulties develop with the Company's process; that Raptor's patents are not sufficient to protect essential aspects of its technology; that competitors may invent better technology; that Raptor's products may not work as well as hoped or worse, that the Company's products may harm recipients; and that Raptor may not be able to raise sufficient funds for development or working capital. As well, Raptor's products may never develop into useful products and even if they do, they may not be approved for sale to the public. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the Securities and Exchange Commission (the "SEC"), which Raptor strongly urges you to read and consider, including its Registration Statement on Form S-1, as amended, that was declared effective on August 7, 2008; its annual report on Form 10-K filed with the SEC on October 30, 2008, as amended by that Form 10-K/A filed with the SEC on December 23, 2008; and its Form 10-Q filed with the SEC on July 15, 2009, all of which are available free of charge on the SEC's web site athttp://www.sec.gov. Subsequent written and oral forward-looking statements attributable to Raptor or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. Raptor expressly disclaims any intent or obligation to update any forward-looking stateme
'/>"/>

SOURCE Raptor Pharmaceuticals Corp. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
2. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp.
3. Smith & Nephew Endoscopys BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability
4. The Glendale Raptors Set Dates for Youth Rugby League and USA Rugby Youth Academy
5. Glendale Raptors Join Four Points by Sheraton Denver Southeast and Animal Planets Dr. Kevin Fitzgerald for Second Annual Halloween Costume Drive & Halloween Party for Kunsberg School at National Jewish Medical and Research Center
6. Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences
7. Smith & Nephew Endoscopys OSTEORAPTOR(TM) Anchor Provides Bioabsorbable Solution for Labral Tears in the Hip and Shoulder
8. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma